Product Description
Calprotectin is a calcium and zinc-binding protein that constitutes 60% of neutrophil cytosolic protein (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4610647/)
Mechanisms of Action: TNF Blocker
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Colombia
Approved Indications: None
Known Adverse Events: None
Company: Bühlmann Laboratories
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Arthritis, Rheumatoid|Osteoarthritis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Infilamatory bowel disease | N/A |
Recruiting |
Inflammatory Bowel Diseases |
2027-07-20 |
|
| ACTRN12624000016538 | N/A |
Not yet recruiting |
Colitis, Ulcerative|Adenomatous Polyposis Coli|Oral Ulcer|Familial Adenomatous Polyposis|Pouchitis|Intestinal Polyposis |
2025-07-01 |
|
| H18-00647 | N/A |
Active, not recruiting |
Colitis, Ulcerative |
2024-12-30 |
|
| NCT06210724 | N/A |
Recruiting |
Colorectal Cancer|Diverticulitis |
2024-09-30 |